Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VBI-2900
- Development stage
- Unknown
- Lead developer
- VBI Vaccines
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**VBI-2900** is a coronavirus vaccine program developed by VBI Vaccines using proprietary enveloped virus-like particle (**eVLP**) technology. It comprises three vaccine candidates: **VBI-2901** (trivalent pan-coronavirus targeting SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins), **VBI-2902** (monovalent against ancestral SARS-CoV-2 Wuhan strain), and **VBI-2905** (monovalent against Beta SARS-CoV-2 variant B.1.351). These eVLP-based vaccines express modified prefusion spike proteins, adjuvanted with aluminum phosphate, eliciting broad neutralizing antibody responses against multiple variants including Omicron, Delta, and bat coronaviruses like RaTG13, with preclinical data showing superior titers compared to convalescent sera and clinical Phase 1 studies demonstrating safety, tolerability, and immunogenicity as boosters.[1][3][5][8]
- Other names
- VBI-2901VBI2901VBI 2901VBI-2902VBI2902VBI 2902VBI-2905VBI2905VBI 2905
Beyond the preview
Go deeper on VBI-2900.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VBI-2900.